Abstract
The purpose of this study was to identify genetic variants predictive of cardiovascular risk factors in a psychiatric population treated with second generation antipsychotics (SGA). 924 patients undergoing treatment for severe mental illness at four US hospitals were genotyped at 1.2. million single nucleotide polymorphisms. Patients were assessed for fasting serum lipid (low density lipoprotein cholesterol [LDLc], high density lipoprotein cholesterol [HDLc], and triglycerides) and obesity phenotypes (body mass index, BMI). Thirteen candidate genes from previous studies of the same phenotypes in non-psychiatric populations were tested for association. We confirmed 8 of the 13 candidate genes at the 95% confidence level. An increased genetic effect size was observed for triglycerides in the psychiatric population compared to that in the cardiovascular population.
Original language | English |
---|---|
Pages (from-to) | 213-219 |
Number of pages | 7 |
Journal | Progress in Neuro-Psychopharmacology and Biological Psychiatry |
Volume | 36 |
Issue number | 2 |
DOIs | |
State | Published - Mar 30 2012 |
Bibliographical note
Funding Information:Supported by the NIH Small Business Innovation Research Grant 2 R44 MH073291-02 “DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics.” The ClinicalTrials.gov identifier for the PIMS study is NCT00752960. Dr. Ruaño is Principal Investigator and Dr. Goethe and Dr. de Leon are co-investigators for this NIH grant.
Keywords
- Antipsychotics
- Lipid metabolism
- Obesity
- Personalized medicine
- Pharmacogenetics
- Triglycerides
ASJC Scopus subject areas
- Pharmacology
- Biological Psychiatry